New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis.
ÌÇÐÄ´«Ã½
Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis. Nature Cho, S., Rhee, S., Madl, C. M., Caudal, A., Thomas, D., Kim, H., Kojic, A., Shin, H. S., Mahajan, A., Jahng, J. W., Wang, X., Thai, P. N., Paik, D. T., Wang, M., Mullen, M., Baker, N. M., Leitz, J., Mukherjee, S., Winn, V. D., Woo, Y. J., Blau, H. M., Wu, J. C. 2025Abstract
Matrix-derived biophysical cues are known to regulate the activation of fibroblasts and their subsequent transdifferentiation into myofibroblasts1-6, but whether modulation of these signals can suppress fibrosis in intact tissues remains unclear, particularly in the cardiovascular system7-10. Here we demonstrate across multiple scales that inhibition of matrix mechanosensing in persistently activated cardiac fibroblasts potentiates-in concert with soluble regulators of the TGFß pathway-a robust transcriptomic, morphological and metabolic shift towards quiescence. By conducting a meta-analysis of public human and mouse single-cell sequencing datasets, we identify the focal-adhesion-associated tyrosine kinase SRC as a fibroblast-enriched mechanosensor that can be targeted selectively in stromal cells to mimic the effects of matrix softening in vivo. Pharmacological inhibition of SRC by saracatinib, coupled with TGFß suppression, induces synergistic repression of key profibrotic gene programs in fibroblasts, characterized by a marked inhibition of the MRTF-SRF pathway, which is not seen after treatment with either drug alone. Importantly, the dual treatment alleviates contractile dysfunction in fibrotic engineered heart tissues and in a mouse model of heart failure. Our findings point to joint inhibition of SRC-mediated stromal mechanosensing and TGFß signalling as a potential mechanotherapeutic strategy for treating cardiovascular fibrosis.
View details for
View details for
View details for